Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-10-16
2007-10-16
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C530S380000, C530S385000, C530S387100, C530S388100, C424S134100, C424S135100, C424S141100, C424S155100, C424S142100, C424S178100, C424S085100, C435S007900, C435S188000, C435S320100
Reexamination Certificate
active
10461885
ABSTRACT:
This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-associated antibody designated PAM4. The invention further relates to humanized and human PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.
REFERENCES:
patent: 5693762 (1997-12-01), Queen et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 6017514 (2000-01-01), Epstein et al.
patent: 6176842 (2001-01-01), Tachibana et al.
patent: 6261537 (2001-07-01), Klaveness et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6632926 (2003-10-01), Chen et al.
patent: 6989140 (2006-01-01), Tidmarsh et al.
patent: 2002/0041847 (2002-04-01), Goldenberg
patent: 2003/0096249 (2003-05-01), Westphal et al.
patent: 2003/0198595 (2003-10-01), Goldenberg et al.
patent: 2005/0002945 (2005-01-01), McBride et al.
Price et al (Tumor Biology 1998, 19:1-20).
Gold et al (Int J Cancer, 1994, 57:204-210).
Ho et al (Semin. Oncol. 1997, 2:187-202).
Walker et al (Pharmaceutical Research, 1995, 12:1548-1553).
Gold, David V., et al., “Characterization of Monoclonal Antibody PAM4 Reactive with A pancreatic Cancer Mucin” Int. J. Cancer: 57, 204-210 (1994) XP-002963400.
Mariani, Giuliano, et al., “Inital Tumor Targeting, Biodistribution, and Pharmacokinetic Evaluation of the Monoclonal Antibody PAM4 in Patients with Pancreatic Cancer” Cancer Research Suppl. 55, 5911s-5915s Dec. 1, 1995.
Gold, David v., et al. “Radioimmunotherapy of Experimental Pancreatic Cancer with 131I-Labeled Monoclonal Antibody PAM4” Int. J. Cancer: 71, 660-667 (1997) XP-002258775.
Gold David V., et al., “Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4” Critical Reviews in Oncology/Hematology 39 (2001) 147-154 XP-002265616.
Cardillo, Thomas M. et al., “Therapeutic Advantage of 90Yttrium-versus 131Iodine-labeled PAM4 Antibody in Experimental Pancreatic Cancer” 3186 vol. 7, 3186-3192, Oct. 2001 Clinical Cancer Research XP-002258776.
Cardillo, Thomas M. “Combined Gemcitabine and Radioimmunotherapy for the Treatment of Pancreatic Cancer” Int. J. Cancer: 97, 386-392 (2002) XP-002265617.
Gold, D. V., et al., “Chimerization and CDR-grafted humanization of PAM4,” Immunology—1993, p. 480 XP-001156924.
Dall'Acqua, William, et al., “Antibody Engineering” 8/198; Engineering and design, pp. 443-450 XP009003344, PD: Aug. 1998.
Kipriyanov, Wergey M., “Generation of Recombinant Antibodies” Molecular Biotechnology, vol. 12, Sep. 1999; pp. 173-201 XP009006067.
Clark, Mike, Antibody humanization: a case of the Emeror's new clothes? Immunology Today vol. 21, No. 8,Aug. 1, 2000, pp. 397-402.
Schuhmacher, Jochen, et al., “Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET” Nuclear Medicine and Biology 28 (2001) 821-828.
Klivenyi, Gabor, et al., “Gallium-68 Chelate Imaging of Human Colon Carcinoma Xenografts Pretargeted with Bispecific Anti-CD44 v6/Anti-Gallium Chelate Antibodies” The Journal of Nuclear Medicine vol. 39, No. 10, Oct. 1998, pp. 1769-1776 XP-002116382.
Karacay, H., et al., “A Pretargeting Bispecific Antibody Method for Improved Imaging and Therapy of Pacreatic Cancer” No. 1484, Poster Sessions Jun. 19, 2002 p. 1484; XP008023949.
Goldenberg David M.
Hansen Hans J.
Qu Zhengxing
Faegre & Benson LLP
Helms Larry R.
Immunomedics Inc.
Tungaturthi Parithosh K.
LandOfFree
Monoclonal antibody hPAM4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody hPAM4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody hPAM4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3901824